Truthring.org | Jan 1, 2007
A 29-year-old ex-soldier who had served 12 months in Afghanistan, upset over orders to deploy to Iraq, was shot to death December 26 after a night-long standoff at a house in Maryland. James E. Dean was notified earlier this month to report to Fort Benning, Georgia, on January 14, 2007, for service in Iraq.
On the evening of Christmas Day, Dean barricaded himself inside his father’s home in rural Leonardstown, about 50 miles southwest of Washington, D.C., near the Chesapeake Bay. Although armed with several weapons, he took no hostages and was apparently a danger only to himself, threatening to commit suicide rather than report for military duty.
Dean had been diagnosed with post-traumatic stress disorder after he returned from Afghanistan in 2005, where he had won awards for service, good conduct and marksmanship as a sergeant leading an infantry unit. He was reportedly suffering from depression and had become dependent on anti-depressant medication.
Since his discharge from the military, Dean had been seeing a Veterans Affairs psychologist and struggling with his combat-related problems, while making progress in his personal life. He got a job as a heating and cooling installer and mechanic and was well regarded by his co-workers. In July 2005, he met his future wife Muriel, marrying her four months ago. This Christmas would have been their first as a married couple.
Xinhua | Jan 5, 2007
With global sales of roughly 4.2 billion dollars last year, Zyprexa is Lilly’s largest-selling drug and a major contributor to the company’s profits.
Lilly said the settlement did not change its view that Zyprexa is a safe and effective treatment for mental illness
The drug maker Eli Lilly and Co. agreed to pay up to 500 million U.S. dollars to settle 18,000 lawsuits from people who claimed they developed diabetes or other diseases after taking Zyprexa, its drug for schizophrenia and bipolar disorder, The New York Times reported Friday.
The agreement brings the total of Zyprexa settlements to at least 1.2 billion dollars, to 28,500 people who said they were injured by the drug. About 20 million people worldwide have taken Zyprexa since its introduction in 1996.
Lilly said the settlement covers cases filed in state and federal courts by law firms or groups of firms for 18,000 clients. This will not affect continuing civil or criminal investigations of Zyprexa by state attorneys general and federal prosecutors.
However, in its statement, Lilly said the settlement did not change its view that Zyprexa is a safe and effective treatment for mental illness.
With global sales of roughly 4.2 billion dollars last year, Zyprexa is Lilly’s largest-selling drug and a major contributor to the company’s profits. Zyprexa is the brand name for olanzapine, a potent chemical that binds to receptors in the brain to reduce psychotic hallucinations and delusions. Clinical trials show that in many patients, Zyprexa also causes severe weight gain and increases in cholesterol and blood sugar.